Imipenem-Relebactam Susceptibility in

Humans beta-Lactamase Inhibitors / pharmacology Portugal Escherichia coli / genetics Spain Anti-Bacterial Agents / pharmacology Imipenem / pharmacology Tazobactam / pharmacology beta-Lactamases / genetics Microbial Sensitivity Tests Klebsiella pneumoniae / genetics Drug Combinations Intensive Care Units
ICU patients Portugal Spain carbapenemase-producing Enterobacterales imipenem-relebactam susceptibility

Journal

Microbiology spectrum
ISSN: 2165-0497
Titre abrégé: Microbiol Spectr
Pays: United States
ID NLM: 101634614

Informations de publication

Date de publication:
26 10 2022
Historique:
pubmed: 1 9 2022
medline: 29 10 2022
entrez: 31 8 2022
Statut: ppublish

Résumé

Imipenem-relebactam is a novel β-lactam-β-lactamase inhibitor combination. We evaluated the

Identifiants

DOI: 10.1128/spectrum.02927-22 PMID: 36043877 PMC: PMC9602286
pubmed: 36043877
doi: 10.1128/spectrum.02927-22
pmc: PMC9602286
doi:

Substances chimiques

relebactam Y1MYA2UHFL
beta-Lactamase Inhibitors 0
Anti-Bacterial Agents 0
Imipenem 71OTZ9ZE0A
Tazobactam SE10G96M8W
beta-Lactamases EC 3.5.2.6
Drug Combinations 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0292722

Références

Clin Microbiol Rev. 2020 Nov 11;34(1):
pubmed: 33177185
Antimicrob Agents Chemother. 2020 Apr 21;64(5):
pubmed: 32152073
Drugs. 2018 Jan;78(1):65-98
pubmed: 29230684
Antibiotics (Basel). 2019 Aug 19;8(3):
pubmed: 31430964
Int J Antimicrob Agents. 2020 Mar;55(3):105887
pubmed: 31926283
JAC Antimicrob Resist. 2020 Oct 22;2(4):dlaa084
pubmed: 34223039
Virulence. 2017 May 19;8(4):460-469
pubmed: 27593176
Int J Antimicrob Agents. 2019 May;53(5):682-688
pubmed: 30769199
Antimicrob Agents Chemother. 2017 Apr 24;61(5):
pubmed: 28223379
Antimicrob Agents Chemother. 2017 May 24;61(6):
pubmed: 28320716
Int J Antimicrob Agents. 2021 Feb;57(2):106259
pubmed: 33310115
J Antimicrob Chemother. 2013 Oct;68(10):2286-90
pubmed: 23696619
Drugs. 2017 Apr;77(6):615-628
pubmed: 28303449
J Antimicrob Chemother. 2012 Jul;67(7):1597-606
pubmed: 22499996
Antimicrob Agents Chemother. 2016 Sep 23;60(10):6234-43
pubmed: 27503659
J Glob Antimicrob Resist. 2018 Dec;15:12-19
pubmed: 29857057
Antimicrob Agents Chemother. 2017 Feb 23;61(3):
pubmed: 28031201
Front Microbiol. 2018 Nov 27;9:2834
pubmed: 30538682
Antimicrob Agents Chemother. 2017 Aug 24;61(9):
pubmed: 28630202
J Antimicrob Chemother. 2021 May 12;76(6):1498-1510
pubmed: 33677560
Antimicrob Agents Chemother. 2010 Mar;54(3):969-76
pubmed: 19995920
Infect Drug Resist. 2020 Nov 25;13:4297-4308
pubmed: 33268997
Lancet Infect Dis. 2011 Jan;11(1):30-8
pubmed: 21126917
Rev Esp Quimioter. 2021 Dec;34(6):668-671
pubmed: 34636220
Antimicrob Agents Chemother. 2015;59(6):3588-92
pubmed: 25779587
Cold Spring Harb Perspect Med. 2016 Aug 01;6(8):
pubmed: 27329032
Clin Microbiol Infect. 2012 May;18(5):413-31
pubmed: 22507109

Auteurs

Marta Hernández-García (M)

Servicio de Microbiología, Hospital Universitario Ramón y Cajalgrid.411347.4-IRYCIS, Madrid, Spain.
CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
ORCID: 0000-0003-2857-2572

María García-Castillo (M)

Servicio de Microbiología, Hospital Universitario Ramón y Cajalgrid.411347.4-IRYCIS, Madrid, Spain.

Germán Bou (G)

CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
Servicio de Microbiología, Hospital Universitario A Coruña, A Coruña, Spain.

Emilia Cercenado (E)

Servicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañóngrid.410526.4, Madrid, Spain.

Mercedes Delgado-Valverde (M)

CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
Unidad Clínica de Enfermedades Infecciosas y Microbiología, Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen Macarena/CSIC/Universidad de Sevilla, Sevilla, Spain.

Antonio Oliver (A)

CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
Servicio de Microbiología, Hospital Universitario Son Espasesgrid.411164.7, Palma de Mallorca, Spain.
ORCID: 0000-0001-9327-1894

Cristina Pitart (C)

Servicio de Microbiología, Hospital Clínic i Provincial, Barcelona, Spain.

Jesús Rodríguez-Lozano (J)

Servicio de Microbiología, Hospital Universitario Marqués de Valdecilla, Santander, Spain.

Nuria Tormo (N)

Servicio de Microbiología, Consorcio Hospital General Universitario de Valencia, Valencia, Spain.

José Melo-Cristino (J)

Laboratório de Microbiologia, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal.

Margarida F Pinto (MF)

Laboratório de Microbiologia, Serviço de Patologia Clínica, Centro Hospitalar Universitário Lisboa Central, Lisboa, Portugal.

Elsa Gonçalves (E)

Laboratório de Microbiologia Clínica, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal.

Valquíria Alves (V)

Laboratório de Microbiologia, Unidade Local de Saúde de Matosinhos, Matosinhos, Portugal.

Ana Raquel Vieira (AR)

Serviço de Patologia Clínica, Centro Hospitalar Universitário São João, Porto, Portugal.

Elmano Ramalheira (E)

Serviço Patologia Clínica, Hospital Infante Dom Pedro, Aveiro, Portugal.

Luísa Sancho (L)

Serviço de Patologia Clínica, Hospital Professor Fernando da Fonseca, Amadora, Portugal.

José Diogo (J)

Serviço de Microbiologia, Hospital Garcia de Orta, Almada, Portugal.

Rui Ferreira (R)

Serviço de Patologia Clínica-Microbiologia, CHUA-Unidade de Portimão, Portimão, Portugal.

Hugo Cruz (H)

Serviço de Microbiologia, Centro Hospitalar Universitário do Porto, Porto, Portugal.

Catarina Chaves (C)

Serviço de Microbiologia, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal.

Joana Duarte (J)

MSD Portugal, Paço de Arcos, Portugal.

Leonor Pássaro (L)

MSD Portugal, Paço de Arcos, Portugal.

Jazmín Díaz-Regañón (J)

Departamento Médico, MSD España, Madrid, Spain.

Rafael Cantón (R)

Servicio de Microbiología, Hospital Universitario Ramón y Cajalgrid.411347.4-IRYCIS, Madrid, Spain.
CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
ORCID: 0000-0003-1675-3173

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Imipenem-Relebactam Susceptibility in
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › Inhibiteurs des bêta-lactamases › Imipenem-Relebactam Susceptibility in
questionsmedicales.fr › Régions géographiques › Europe › Portugal › Imipenem-Relebactam Susceptibility in
questionsmedicales.fr › Bactéries › Proteobacteria › Gammaproteobacteria › Enterobacteriaceae › Escherichia › Escherichia coli › Imipenem-Relebactam Susceptibility in
questionsmedicales.fr › Régions géographiques › Europe › Espagne › Imipenem-Relebactam Susceptibility in
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › Imipenem-Relebactam Susceptibility in
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › bêta-Lactames › Carbapénèmes › Thiénamycine › Imipénem › Imipenem-Relebactam Susceptibility in
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › bêta-Lactames › Pénicillines › Acide pénicillanique › Tazobactam › Imipenem-Relebactam Susceptibility in
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Hydrolases › Amidohydrolases › bêta-Lactamases › Imipenem-Relebactam Susceptibility in
questionsmedicales.fr › Techniques d'investigation › Évaluation préclinique de médicament › Tests de sensibilité microbienne › Imipenem-Relebactam Susceptibility in
questionsmedicales.fr › Bactéries › Proteobacteria › Gammaproteobacteria › Enterobacteriaceae › Klebsiella › Klebsiella pneumoniae › Imipenem-Relebactam Susceptibility in
questionsmedicales.fr › Préparations pharmaceutiques › Association médicamenteuse › Imipenem-Relebactam Susceptibility in
questionsmedicales.fr › Établissements, main d'oeuvre et services de soins de santé › Établissements de santé › Unités hospitalières › Unités de soins intensifs › Imipenem-Relebactam Susceptibility in